Profile data is unavailable for this security.
About the company
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KαH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3Kα and has multiple programs designed to enable targeting of this key oncogene.
- Revenue in USD (TTM)0.00
- Net income in USD-41.03m
- Incorporated2014
- Employees8.00
- LocationOnkure Therapeutics Inc6707 Winchester Circle, Suite 400BOULDER 80301United StatesUSA
- Phone+1 (720) 307-2892
- Fax+1 (302) 674-5266
- Websitehttps://onkuretherapeutics.com/
More ▼
Mergers & acquisitions
| Acquired company | OKUR:NMQ since announced | Transaction value |
|---|---|---|
| OnKure Inc | -6.74% | 170.00m |
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2Seventy Bio Inc | 44.12m | -156.25m | 212.69m | 274.00 | -- | 0.9057 | -- | 4.82 | -3.06 | -3.06 | 0.8417 | 4.56 | 0.0721 | -- | 1.42 | 161,021.90 | -25.54 | -- | -28.17 | -- | 66.39 | 91.76 | -354.16 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| XBiotech Inc | 0.00 | -35.01m | 216.29m | 94.00 | -- | 1.10 | -- | -- | -1.15 | -1.15 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -15.53 | 31.88 | -16.32 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0484 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Kyverna Therapeutics Inc | -100.00bn | -100.00bn | 218.32m | 112.00 | -- | 0.6546 | -- | -- | -- | -- | -- | 7.73 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -44.32m | 219.84m | 25.00 | -- | 3.66 | -- | -- | -0.4412 | -0.4412 | 0.00 | 0.7815 | 0.00 | -- | -- | 0.00 | -53.78 | -47.39 | -58.89 | -54.41 | -- | -- | -- | -- | -- | -- | 0.001 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 221.00m | 145.00 | -- | 1.48 | -- | 3.07 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -38.70m | 221.30m | 19.00 | -- | 1.47 | -- | -- | -4.69 | -4.69 | 0.00 | 12.36 | 0.00 | -- | -- | 0.00 | -38.61 | -86.84 | -49.21 | -130.46 | -- | -- | -- | -769.76 | -- | -- | 0.00 | -- | -- | -- | -5.33 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 81.63m | -20.23m | 222.15m | 76.00 | -- | 0.8094 | -- | 2.72 | -0.3507 | -0.3507 | 1.31 | 4.40 | 0.2746 | -- | 29.13 | 1,074,079.00 | -6.81 | -50.55 | -7.14 | -55.91 | -- | -- | -24.79 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Solid Biosciences Inc | 0.00 | -102.44m | 222.15m | 88.00 | -- | 1.30 | -- | -- | -3.04 | -3.04 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -51.66 | -49.99 | -57.25 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0081 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Onkure Therapeutics Inc | 0.00 | -41.03m | 225.17m | 8.00 | -- | 0.7625 | -- | -- | -12.25 | -12.25 | 0.00 | 22.14 | 0.00 | -- | -- | 0.00 | -39.45 | -- | -42.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -96.49m | 228.05m | 59.00 | -- | 2.75 | -- | -- | -1.55 | -1.55 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -55.29 | -45.00 | -60.60 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3554 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Compass Therapeutics Inc. | 850.00k | -47.76m | 232.53m | 32.00 | -- | 1.68 | -- | 273.56 | -0.3553 | -0.3553 | 0.0063 | 1.01 | 0.0053 | -- | -- | 26,562.50 | -29.93 | -41.75 | -31.25 | -46.41 | -- | -- | -5,618.71 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Amarin Corporation plc (ADR) | 241.02m | -39.35m | 234.26m | 275.00 | -- | 0.4408 | -- | 0.9719 | -0.0959 | -0.0959 | 0.5876 | 1.29 | 0.3032 | 0.4387 | 2.05 | 876,440.00 | -4.95 | -4.48 | -7.02 | -6.54 | 56.46 | 75.70 | -16.32 | -8.59 | 2.11 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Nektar Therapeutics | 93.14m | -168.30m | 235.62m | 137.00 | -- | 4.83 | -- | 2.53 | -0.8371 | -0.8371 | 0.4634 | 0.265 | 0.2483 | 3.96 | 84.52 | 679,832.10 | -44.87 | -31.02 | -53.39 | -34.63 | 67.80 | 78.04 | -180.70 | -372.21 | 4.24 | -15.53 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| MacroGenics Inc | 141.33m | -97.62m | 236.62m | 339.00 | -- | 1.97 | -- | 1.67 | -1.57 | -1.57 | 2.26 | 1.91 | 0.4676 | 3.24 | 8.30 | 416,899.70 | -32.30 | -37.76 | -39.53 | -45.53 | 95.07 | -- | -69.07 | -133.96 | 3.69 | -93.94 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Climb Bio Inc | 0.00 | -64.20m | 236.72m | 9.00 | -- | 1.06 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Data as of Nov 13 2024. Currency figures normalised to Onkure Therapeutics Inc's reporting currency: US Dollar USD
6.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 22 Oct 2024 | 660.14k | 0.00% |
| BML Capital Management LLCas of 07 Oct 2024 | 345.74k | 0.00% |
| Octagon Capital Advisors LPas of 04 Oct 2024 | 225.00k | 0.00% |
| Lundbeckfond Invest A/Sas of 15 Mar 2024 | 203.12k | 6.08% |
| Perceptive Advisors LLCas of 04 Oct 2024 | 100.44k | 0.00% |
More ▼
Data from 15 Mar 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
